Eversept Partners, LP Exelixis, Inc. Transaction History

Eversept Partners, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $3.54 Million - $4.71 Million	-203,156 Closed	0 $0
Q1 2022 Nov 08, 2023	BUY	$17.03 - $22.67 $3.46 Million - $4.61 Million	203,156 New	203,156 $4.61 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $5.66 Million - $7.54 Million	-332,544 Reduced 62.08%	203,156 $4.61 Million
Q4 2021 Nov 08, 2023	BUY	$15.84 - $21.88 $307,185 - $424,318	19,393 Added 3.76%	535,700 $9.79 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $307,185 - $424,318	19,393 Added 3.76%	535,700 $9.79 Million
Q3 2021 Nov 08, 2023	BUY	$16.3 - $21.14 $5.48 Million - $7.11 Million	336,307 Added 186.84%	516,307 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $5.48 Million - $7.11 Million	336,307 Added 186.84%	516,307 $10.9 Million
Q2 2021 Nov 08, 2023	BUY	$17.95 - $25.56 $3.23 Million - $4.6 Million	180,000 New	180,000 $3.28 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $3.23 Million - $4.6 Million	180,000 New	180,000 $3.28 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.